miR-382 inhibits tumor growth and enhance chemosensitivity in osteosarcoma

// Meng Xu 1 , Hua Jin 2 , Cheng-Xiong Xu 3 , Bo Sun 4 , Zhi Mao 1 , Wen-Zhi Bi 1 , Yan Wang 1 1 Department of Orthopaedics, The General Hospital of Chinese People's Liberation Army, Beijing, China. 2 Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA. 3 Departments of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. 4 State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China. Correspondence to: Dr. Cheng-Xiong Xu, e-mail: xuchengxiong@hanmail.net Yan Wang, e-mail: leptin1@gmail.com Keywords: miR-382, osteosarcoma growth, chemoresistance Received: July 11, 2014      Accepted: August 28, 2014      Published: September 05, 2014 ABSTRACT Dysregulation of miRNAs is involved in osteosarcoma (OS). Here, we demonstrate that miR-382 is decreased in specimens of OS patients with a poor chemoresponse compared to those with a good chemoresponse. In addition, our clinical data show that decreased miR-382 was associated with poor survival in OS patients. Overexpression of miR-382 inhibited cell growth and chemoresistance by targeting KLF12 and HIPK3, respectively. In contrast, inhibition of miR-382 or overexpression of target genes stimulated OS cell growth and chemoresistance both in vitro and in vivo . Taken together, these findings suggest that miR-382 is a tumor suppressor miRNA and induction of miR-382 is a potential strategy to inhibit OS progression.